<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02411825</url>
  </required_header>
  <id_info>
    <org_study_id>TDR13700</org_study_id>
    <secondary_id>2014-004216-10</secondary_id>
    <secondary_id>U1111-1163-1209</secondary_id>
    <nct_id>NCT02411825</nct_id>
  </id_info>
  <brief_title>Multiple Ascending Dose Study in Healthy Male Subjects and Overweight to Obese Male and Female Type 2 Diabetes Mellitus (T2DM) Patients</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of Repeated Subcutaneous Doses of SAR425899 in Healthy Male Subjects and Overweight to Obese Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To assess in healthy adult male subjects:&#xD;
&#xD;
        -  The tolerability and safety of 21-day repeated subcutaneous (SC) doses of SAR425899&#xD;
           including two up titration steps.&#xD;
&#xD;
        -  Pharmacokinetic (PK) parameters of SAR425899 after ascending repeated SC doses in&#xD;
           plasma.&#xD;
&#xD;
        -  Pharmacodynamic (PD) effects on fasting and postprandial plasma glucose, insulin,&#xD;
           biomarkers of lipid metabolism and fibroblast growth factor 21 (FGF21).&#xD;
&#xD;
      To assess in overweight to obese T2DM mellitus patients:&#xD;
&#xD;
        -  The tolerability and safety after 28-day repeated SC doses of SAR425899 including 2 up&#xD;
           titration steps.&#xD;
&#xD;
        -  PK parameters of SAR425899 after ascending repeated SC doses in plasma and urine.&#xD;
&#xD;
        -  PD effects on fasting and postprandial plasma glucose, insulin, C-peptide, incretin&#xD;
           panel (total and active ghrelin, total peptide YY [PYY], total and active glucagon-like&#xD;
           peptide -1 [GLP-1], glucagon and total gastric inhibitory polypeptide-1 [GIP]), body&#xD;
           weight, FGF21, biomarkers of lipid metabolism and HbA1c.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total study duration is approximately 10-15 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>28 to 35 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in vital signs</measure>
    <time_frame>28 to 35 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in physical examination</measure>
    <time_frame>28 to 35 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ECG</measure>
    <time_frame>28 to 35 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in clinical laboratory parameters (hematology)</measure>
    <time_frame>28 to 35 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in clinical laboratory parameters (biochemistry)</measure>
    <time_frame>28 to 35 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in body temperature</measure>
    <time_frame>28 to 35 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in biomarkers (FGF21)</measure>
    <time_frame>28 to 35 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in biomarkers (lipid biomarker)</measure>
    <time_frame>28 to 35 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in biomarkers (incretins)</measure>
    <time_frame>28 to 35 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of pharmacokinetic parameters in blood (AUC)</measure>
    <time_frame>28 to 35 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of pharmacokinetic parameters in blood (Cmax)</measure>
    <time_frame>28 to 35 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of pharmacokinetic parameters in blood (t1/2)</measure>
    <time_frame>28 to 35 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of pharmacokinetic parameters in urine (Ae0-24)</measure>
    <time_frame>28 to 35 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of pharmacokinetic parameters in urine (fe0-24)</measure>
    <time_frame>28 to 35 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Body weight</measure>
    <time_frame>28 to 35 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Fasting Blood Glucose</measure>
    <time_frame>28 to 35 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Postprandial Blood Glucose</measure>
    <time_frame>28 to 35 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in postprandial Insulin</measure>
    <time_frame>28 to 35 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in postprandial C-peptide profiles</measure>
    <time_frame>28 to 35 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in HbA1c</measure>
    <time_frame>28 to 35 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>SAR425899 (healthy subjects)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily SC doses of SAR425899</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (healthy subjects)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Once daily SC doses of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAR425899 (T2DM Patients)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily SC doses of SAR425899 and two up titration steps in each dose cohort with metformin as background therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (T2DM Patients)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Once daily SC doses of placebo and two up titration steps in each dose cohort with metformin as background therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAR425899</intervention_name>
    <description>Pharmaceutical form: solution for injection&#xD;
Route of administration: subcutaneous</description>
    <arm_group_label>SAR425899 (T2DM Patients)</arm_group_label>
    <arm_group_label>SAR425899 (healthy subjects)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Pharmaceutical form: solution for injection&#xD;
Route of administration: subcutaneous</description>
    <arm_group_label>Placebo (T2DM Patients)</arm_group_label>
    <arm_group_label>Placebo (healthy subjects)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
    <description>Pharmaceutical form: tablet&#xD;
Route of administration: oral</description>
    <arm_group_label>Placebo (T2DM Patients)</arm_group_label>
    <arm_group_label>SAR425899 (T2DM Patients)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        Healthy subjects:&#xD;
&#xD;
          -  Males, between 18 and 55 years of age, inclusive.&#xD;
&#xD;
          -  Body mass index (BMI) between 20.0 and 30.0 kg/m^2, inclusive; body weight between&#xD;
             50.0 and 120.0 kg, inclusive.&#xD;
&#xD;
          -  Certified as healthy by comprehensive clinical assessment (detailed medical history,&#xD;
             complete physical examination). Comorbidities of higher weight (eg, mild impaired&#xD;
             glucose tolerance, mild hypertension, mild hyperlipidemia) are permitted unless, per&#xD;
             investigator, these conditions hamper participation.&#xD;
&#xD;
          -  Normal vital signs after 10 minutes resting supine:&#xD;
&#xD;
          -  95 mmHg &lt;systolic blood pressure (SBP) &lt;150 mmHg.&#xD;
&#xD;
          -  45 mmHg &lt;diastolic blood pressure (DBP) &lt;100 mmHg.&#xD;
&#xD;
          -  50 bpm &lt;heart rate (HR) &lt;100 bpm.&#xD;
&#xD;
          -  Standard 12-lead electrocardiogram (ECG) parameters after 10 minutes resting in supine&#xD;
             position within; 120 ms &lt;PR &lt;220 ms, QRS &lt;120 ms, QTc ≤430 ms, normal ECG.&#xD;
&#xD;
          -  Normal 24-hour Holter electrocardiography at screening.&#xD;
&#xD;
          -  Laboratory parameters within normal range; however serum creatinine, alkaline&#xD;
             phosphatase, hepatic enzymes (aspartate aminotransferase, alanine aminotransferase),&#xD;
             and total bilirubin (unless subject has Gilbert syndrome) should not exceed upper&#xD;
             laboratory norm (ULN).&#xD;
&#xD;
        T2DM patients:&#xD;
&#xD;
          -  Males and females, 18-70 years of age.&#xD;
&#xD;
          -  Body weight 50.0-150.0 kg, BMI 28.0 - 42.0 kg/m^2.&#xD;
&#xD;
          -  Diagnosis of T2DM for at least 1 year with stable metformin prior to inclusion;&#xD;
             comorbidities related to T2DM but otherwise healthy.&#xD;
&#xD;
          -  Normal vital signs supine:&#xD;
&#xD;
          -  95 mmHg &lt; SBP &lt;160 mmHg&#xD;
&#xD;
          -  45 mmHg &lt; DBP &lt;100 mmHg&#xD;
&#xD;
          -  50 bpm &lt; HR &lt;100 bpm&#xD;
&#xD;
          -  Normal standard 12-lead ECG in supine position unless abnormality is clinically&#xD;
             irrelevant.&#xD;
&#xD;
          -  Laboratory parameters in normal range unless abnormality is clinically irrelevant or&#xD;
             strongly associated with T2DM; total bilirubin not to exceed ULN.&#xD;
&#xD;
          -  Fasting plasma glucose ≥90 mg/dL.&#xD;
&#xD;
          -  HbA1c ≥6.5% and ≤8.5%.&#xD;
&#xD;
          -  Females: Sterilization at least 3 months before inclusion or postmenopausal.&#xD;
&#xD;
        Both:&#xD;
&#xD;
          -  Signed written informed consent.&#xD;
&#xD;
          -  Not supervised/confined for legal or administrative reasons.&#xD;
&#xD;
          -  Male subject with partner of childbearing potential (including lactating women) must&#xD;
             use double contraception method.&#xD;
&#xD;
          -  Male subject with pregnant partner must use a condom up to 2 months after last dosing.&#xD;
&#xD;
          -  Male subject agreed not to donate sperm up to 2 months after last dosing.&#xD;
&#xD;
          -  Not undergoing physical training program/planning changes in activity; not vegetarian&#xD;
             or following special diet.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        Healthy subjects:&#xD;
&#xD;
          -  History of clinically relevant disease/signs of acute illness.&#xD;
&#xD;
          -  History of drug hypersensitivity/allergic disease.&#xD;
&#xD;
          -  Smoking more than 5 cigarettes/day.&#xD;
&#xD;
          -  Any medication within 14 days before inclusion or within 5 times&#xD;
             elimination/pharmacodynamic half-life of the medication and during study; vaccination&#xD;
             within last 28 days, biologics given within 4 months before inclusion.&#xD;
&#xD;
        T2DM patients:&#xD;
&#xD;
          -  History/presence of clinically relevant disease/signs of acute illness not related to&#xD;
             patient's metabolic status.&#xD;
&#xD;
          -  History/presence of drug hypersensitivity or allergic disease.&#xD;
&#xD;
          -  Smoking more than 5 cigarettes per day.&#xD;
&#xD;
          -  If female, pregnancy/breast-feeding.&#xD;
&#xD;
          -  Any intake of medication during treatment period and within 21 days before first&#xD;
             dosing or within 5 times half-life of the medication, except: metformin, standard&#xD;
             antihypertensive treatment, statins, acetyl salicylic acid.&#xD;
&#xD;
          -  Thyroid hormone replacement is allowed if dose was stable for 3 months prior to&#xD;
             screening.&#xD;
&#xD;
          -  Individual background therapy, considered necessary for the patient's welfare, that&#xD;
             could not be discontinued for the duration of the study, may be given at the&#xD;
             discretion of the Investigator, with a stable dose (when possible) and only if its&#xD;
             intake is unlikely to interfere with the investigational product.&#xD;
&#xD;
          -  Treated with sulphonyl-ureas up to 3 months, proton pump inhibitors up to 1 week prior&#xD;
             to dosing.&#xD;
&#xD;
          -  Vaccination within last 28 days, any biologics within 4 months before inclusion.&#xD;
&#xD;
          -  Severe hypoglycemia resulting in seizure/unconsciousness/coma/hospitalization for&#xD;
             diabetic ketoacidosis in last 3 months before screening.&#xD;
&#xD;
          -  Persistent hyperglycemia not controlled by metformin/diet/exercise.&#xD;
&#xD;
          -  Diabetic neuropathy, retinopathy, nephropathy or renal impairment.&#xD;
&#xD;
          -  Hepatic impairment.&#xD;
&#xD;
          -  Unstable hypo- or hyperthyroidism.&#xD;
&#xD;
        Both:&#xD;
&#xD;
          -  Headaches/migraine.&#xD;
&#xD;
          -  Recurrent nausea/vomiting.&#xD;
&#xD;
          -  Blood donation within 1 month before inclusion.&#xD;
&#xD;
          -  Symptomatic postural hypotension, irrespective of decrease in BP, or asymptomatic&#xD;
             postural hypotension defined as decrease in SBP ≥20 mmHg within 3 minutes when&#xD;
             changing from supine to standing.&#xD;
&#xD;
          -  History/presence of drug or alcohol abuse.&#xD;
&#xD;
          -  Positive result: hepatitis B surface antigen, anti-hepatitis C virus antibodies,&#xD;
             anti-human immunodeficiency virus 1 and 2 antibodies.&#xD;
&#xD;
          -  Any condition affecting gastric emptying or absorption from GI tract.&#xD;
&#xD;
          -  Surgically treated obesity, bariatric surgery.&#xD;
&#xD;
          -  Severe dyslipidemia with fasting triglycerides &gt;450 mg/dL.&#xD;
&#xD;
          -  History of pancreatitis or pancreatectomy.&#xD;
&#xD;
          -  Amylase/lipase &gt;3 ULN.&#xD;
&#xD;
          -  History of thyroid cancer or a genetic condition that predisposes to thyroid cancer.&#xD;
&#xD;
          -  Elevated basal calcitonin.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 276001</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>March 24, 2015</study_first_submitted>
  <study_first_submitted_qc>April 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2015</study_first_posted>
  <last_update_submitted>June 14, 2018</last_update_submitted>
  <last_update_submitted_qc>June 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

